Core Viewpoint - Dividend investing can build wealth and provide passive income, with dividend stocks outperforming non-dividend payers in the long run [1] Group 1: Dividend Stocks Overview - Dividend stocks can be ideal long-term investments even for those focused on growth stocks, as they provide stability during market fluctuations [2] - Companies that are essential in their industries and offer in-demand products and services are key targets for dividend investing [2] Group 2: Verizon Communications - Verizon is a leading telecom company in the U.S. with over 146 million wireless customers, playing a significant role in the economy [4] - The company is expanding its broadband business and plans to add over 2.2 million new fiber subscribers through the acquisition of Frontier Communications [5] - Verizon's stock has a yield of 7.01%, a payout ratio of 57.68%, and has raised dividends for 21 consecutive years, paying an annual dividend of $2.76 per share [5] - Despite recent struggles in gaining new wireless customers, Verizon is viewed as a long-term stability and dividend investment opportunity [7] Group 3: Johnson & Johnson - Johnson & Johnson is now a pure-play health company focusing on medical technology and innovative drugs, operating in a non-cyclical industry [8] - The stock has a yield of 2.37%, priced at $219.57, and has gained 48% over the past year [9] - The company reported a 4.4% year-over-year revenue increase and a 15.7% EPS jump in the third quarter, generating $14.3 billion in free cash flow in the first nine months of 2025 [10] - Johnson & Johnson has a payout ratio of 48.94%, has increased dividends for 63 years, and pays an annual dividend of $5.20 per share with a 5-year dividend growth rate of 5.25% [12] Group 4: Coca-Cola - Coca-Cola is a blue-chip dividend stock with a yield of 2.89%, having raised dividends for 63 consecutive years [13] - The stock is priced at $70.48, with a 13% gain over the past year, and has a payout ratio of 67.85%, paying an annual dividend of $2.04 per share [14] - Coca-Cola operates an asset-light business model, selling concentrates and syrups to bottling partners, which minimizes operating costs and generates steady revenue [15] - The company has demonstrated resilience, generating over 100% total return over the past decade, making it a reliable choice for dividend investors [16]

Core Viewpoint - Ventripoint Diagnostics Ltd. has successfully closed a non-brokered private placement, raising a total of $1,009,772 through the issuance of 10,097,720 units at a price of $0.10 per unit, with significant insider participation [1][4]. Group 1: Offering Details - Each unit consists of one common share and one common share purchase warrant, with warrants priced at $0.13 and valid for 24 months [2]. - The company has paid cash finder's fees of $15,600 and issued 156,000 Finder's Warrants, also exercisable at $0.13 for 24 months [3]. - The offering is classified as a related party transaction, with insiders purchasing 1,393,400 units, representing 13.8% of total proceeds [4]. Group 2: Use of Proceeds - Proceeds from the offering will be allocated to operational costs, sales and marketing, hiring additional key personnel, and general working capital [5]. Group 3: Regulatory and Compliance Information - All securities issued will be subject to a hold period of four months plus one day from the closing date, pending approval from the Exchange [6]. - The securities are not registered under the U.S. Securities Act and cannot be sold in the U.S. without proper registration or exemption [7]. Group 4: Company Overview - Ventripoint is recognized as a leader in applying AI to echocardiography, with its VMS+ products providing accurate cardiac measurements comparable to MRI, enhancing patient care [9].

Core Insights - The article discusses the development of a generative foundation model for continuous glucose monitoring (CGM) data called GluFormer, which has significant predictive capabilities for both short-term glucose parameters and long-term disease risk stratification, particularly for diabetes and cardiovascular mortality [4][6]. Group 1: Model Development - The GluFormer model was trained using over 10 million glucose measurements from 10,812 adults, primarily non-diabetic, and employs self-supervised learning [5]. - The model's representations can be transferred across 19 external cohorts, covering five countries and various CGM devices, demonstrating continuous improvement in predicting glucose parameters compared to baseline glucose and HbA1c levels [5]. Group 2: Risk Stratification - In individuals with prediabetes, GluFormer effectively stratified risk for those likely to experience clinically significant HbA1c increases within two years, outperforming baseline HbA1c and common CGM metrics [6]. - In a cohort of 580 adults with a median follow-up of 11 years, GluFormer identified 66% of new diabetes cases and 69% of cardiovascular mortality cases in the highest risk quartile, compared to only 7% and 0% in the lowest risk quartile [6]. Group 3: Multimodal Integration - The research team also developed a multimodal extension of GluFormer that integrates dietary data, allowing for the generation of reasonable glucose trajectories and predictions of individual glucose responses to food [7]. - Overall, GluFormer provides a scalable framework for encoding glucose patterns, enhancing both short-term glucose predictions and long-term disease risk stratification, thus offering a powerful tool for precision medicine and metabolic health management [7].

Market Overview - The S&P 500 has increased by 17% over the past year and 2.5% over the past month, currently surpassing the 6,950 mark with 7,300 as a potential target [1] - A rotation is occurring in the market, with mega-cap tech stocks cooling while overall breadth improves, indicating a shift towards more diverse growth across small caps and energy stocks [2] - Despite modest upside forecasts for the S&P 500 in 2026, rising valuation metrics and ongoing volatility may lead to selective trimming of positions [2][3] Company-Specific Insights Tesla (TSLA) - Tesla shares are currently trading at $440, down approximately 9% over the last month, facing rising price pressures and increased competition, particularly from BYD in China [4] - Deliveries fell by about 8.6% year-over-year, and the Cybertruck is underperforming in sales volume [4] - Major fund managers, including ARK Innovation ETF, are reducing their Tesla holdings, indicating a lack of confidence in the stock's future performance [4] GE HealthCare Technologies (GEHC) - GE HealthCare Technologies is trading at $82 per share, with sales in China declining by approximately 11% and 18% year-over-year in the first and second quarters of 2024, respectively [6] - The company has been downgraded by UBS due to competitive pressures and risks from rising generics that are not fully priced in [6] - Despite a steady dividend payout of 0.18%, the stock faces limited upside and increased competition in the medical technology market [8] UnitedHealth (UNH) - UnitedHealth shares are trading at less than $340, down 34% over the past year, primarily due to rising medical costs and a significant drop in Medicaid margins projected to decline from -0.1% in 2025 to -1.8% in 2026 [9] - The company has faced management challenges, including curbing earnings guidance and scrutiny over diagnosis practices, leading to increased uncertainty [10] - Analysts suggest selling UNH shares until clearer visibility on its performance emerges [10]

As filed with the Securities and Exchange Commission on January 16, 2026. Registration No. 333-291993 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________ AMENDMENT NO.1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ______________________________ HELIX ACQUISITION CORP. III (Exact name of registrant as specified in its charter) ______________________________ | Cayman Islands | 6770 | N/A | | --- | --- | --- | | (State or other jurisdict ...

转自：新华财经 在创新驱动发展战略深入实施背景下，科技企业孵化器正从基础服务"空间载体"向产业生态"创新引擎"深度转型。位于北京丰台科技园东区建设先导区的中 都科技大厦，通过构建"平台+培训+资金"三维赋能体系，打造细分领域垂直孵化模式，为产业培育新机制探索提供了实践样本。 打造多元适配空间 筑牢创新硬件基础 编辑：赵鼎 依托丰台区优质医疗资源集聚优势，中都科技大厦搭建首科医谷医学成果转化平台，聚焦医学创新细分领域，提供概念验证、临床资源对接、知识产权管理 全链条服务。六年来，该平台累计服务医学成果转化项目135项，推动申请专利及知识产权273件，开展概念验证68项，实现技术合同成交额超5000万元。目 前，园区正筹建中都医工大厦，从排水、排风、结构设计等维度，为医疗类科研企业提供专业化办公配套。 贯通全周期资本通道 强化政策协同赋能 资金支持是破解创新企业"死亡之谷"的关键。中都孵化器副总经理孙飞介绍，"市场上不少小微企业倒在了融资黎明之前。中都以行稳致远的心态进行投 资，不求'暴击'翻倍的投资回报，旨在帮助初创企业度过'死亡谷'阶段。" 据悉，中都科技大厦成立和新星创投基金，以5000万元自有资金为启动资 ...

Group 1: AI in Healthcare - AI is becoming integral to enhancing patient experiences in healthcare, as noted by UCSF Health CEO Suresh Gunasekaran, who emphasizes the transformation in medical education and practice due to AI [1] - Providence CEO Erik Wexler highlights the significant impact of AI on addressing staff shortages and rising costs in healthcare, describing it as "life-changing technology" [2] - The potential for AI to reduce healthcare costs is welcomed by many Americans, with healthcare expected to account for nearly 19% of U.S. GDP this year, reflecting ongoing affordability challenges [2] Group 2: Economic Context and Business Outlook - U.S. Chamber of Commerce President Suzanne P. Clark points out persistent issues of affordability and access to healthcare, drawing parallels to economic conditions during the 1976 bicentennial [3] - Clark notes a threefold increase in GDP, a 40% rise in median household income, and transformative technologies as indicators of progress despite challenges [4] - The focus for business leaders in the AI era is on accelerating adoption while managing costs, with a call for AI to improve access, quality, and reduce staff burden in healthcare [4]

Core Viewpoint - Hologic, Inc. plans to release its financial results for the first quarter of fiscal 2026 on January 29, after market close, and will not host a quarterly conference call or provide financial guidance due to its pending acquisition by Blackstone and TPG [1]. Company Overview - Hologic, Inc. is an innovative medical technology company focused on improving women's health and well-being through early detection and treatment [2].

Company Overview - Axogen focuses on restoring peripheral nerve function to improve health and quality of life for patients [3] Leadership and Vision - The company is led by President and CEO Mike Dale, who has been in this role for over 1.5 years and aims to share the opportunities and purposes behind Axogen [2] Industry Context - Axogen operates within the med tech industry, which is dedicated to enhancing health outcomes and patient experiences through innovative medical technologies [3]

BROSSARD, Quebec, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces the engagement of Investor Brand Network (“IBN”) to provide corporate communication and awareness solutions to the Corporation. As per the agreement signed between IBN and DIAGNOS, IBN is entitled to a monthly compensation of US$6,400, pay ...